analyzeportfolio
Nasdaq · Financials

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

As-reported financials and SEC filings for CLOVER HEALTH INVESTMENTS, CORP. /DE. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About CLOVER HEALTH INVESTMENTS, CORP. /DE

Clover Health Investments, Corp. provides Medicare Advantage plans that use a proprietary software platform called Clover Assistant to help physicians identify, manage, and treat chronic diseases earlier. The company offers Preferred Provider Organization and Health Maintenance Organization plans with wide physician networks and low out-of-pocket costs, primarily serving Medicare-eligible seniors, including those in underserved markets. Clover Health also operates a home-based primary care program for high-acuity members and offers its technology platform as a service to external payors and providers through its subsidiary, Counterpart Health.

Snapshot

Revenue
$1.92B
Revenue growth (YoY)
40.3%
Net income
$-85.5M
Diluted EPS
Gross margin
Operating margin
-4.4%
Net margin
-4.4%
FCF margin
-3.6%
ROE
-27.7%
net income / fiscal-year-end equity
P/E
trailing when available, otherwise FY EPS
Market cap
$2.28B
Long-term debt / equity
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Clover Health Investments, Corp. /de

  • Revenue grew 40.3% to $1.9B in FY2025, faster than the 8.8% the year before.
  • Operating margin is -4.4% in FY2025, +38.8 pp against -43.3% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $743M, up 55.6% from Q2 FY2025.
  • Free cash flow was negative $69M in FY2025.
  • Net loss widened to $86M in FY2025, from $43M in FY2024.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Clover Health Investments, Corp. /de’s fundamentals sit among the 425 Financials companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Operating margin-4.4%
23rd percentile of 146
Net margin-4.4%
12th percentile of 377
FCF margin-3.6%
17th percentile of 272
Revenue growth (YoY)+40.3%
83rd percentile of 420
ROE-27.7%
12th percentile of 375
Short interest4.98d
62nd percentile of 420

Clover Health Investments, Corp. /de’s net margin of -4.4% ranks in the 12th percentile of the 377 Financials companies reporting it. Clover Health Investments, Corp. /de’s return on equity of -27.7% ranks in the 12th percentile of the 375 Financials companies reporting it.

No reported insider purchases (code P) in the last 90 days; 17 insider sales totaling $3.1M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 6 quant / multi-strat books among the superinvestors we track; no conviction manager currently reports a position.

Conviction investors
0
+6 quant / multi-strat
Initiated / added
4
0 new, 4 added
Reduced / exited
2
2 trimmed, 0 exited
Combined position
$50.3M
reported long value
InvestorAs ofPosition valueSharesChange
Renaissance TechnologiesquantQ2 2026$14.7M2.8MReduced
Citadel AdvisorsquantQ2 2026$11.3M2.2MAdded
D. E. ShawquantQ2 2026$10.3M2.0MAdded
Millennium ManagementquantQ2 2026$5.8M1.1MReduced
Point72 Asset ManagementquantQ2 2026$5.6M1.1MAdded
AQR Capital ManagementquantQ2 2026$2.6M488.2KAdded

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
17
$3.1M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-17
THORNTON JOSEPH CLAYInterim CFOSell17.8K$4.39$78K
2026-08-10
Toy AndrewChief Executive OfficerSell87.8K$4.65$408K
2026-07-20
Soares KarenChief Legal OfficerSell51.7K$4.51$233K
2026-07-17
Reynoso Jamie L.CEO, Medicare AdvantageSell4.8K$4.53$22K
2026-07-15
filed 2026-07-16
Toy AndrewChief Executive OfficerSell62.7K$4.67$293K
2026-07-15
filed 2026-07-16
Wai ConradCEO, Counterpart HealthSell24.2K$4.67$113K
2026-07-15
filed 2026-07-16
Reynoso Jamie L.CEO, Medicare AdvantageSell13.1K$4.67$61K
2026-07-15
filed 2026-07-16
Soares KarenChief Legal OfficerSell10.5K$4.67$49K
2026-07-15
filed 2026-07-16
THORNTON JOSEPH CLAYInterim CFOSell4.6K$4.67$22K
2026-07-08
filed 2026-07-09
Reynoso Jamie L.CEO, Medicare AdvantageSell2.4K$4.68$11K
2026-07-06
Reynoso Jamie L.CEO, Medicare AdvantageSell6.2K$5.26$33K
2026-07-01
Toy AndrewChief Executive OfficerSell313.5K$5.32$1.7M

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
26.1M
settled 2026-08-14
Change vs prior
-7.4%
vs previous settlement
Days to cover
4.98
at avg daily volume
Avg daily volume
5.2M
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-1426.1M-7.4%4.98
2026-07-3128.2M-1.8%7.18
2026-07-1528.7M+29.6%4.89
2026-06-3022.2M-10.7%2.80
2026-06-1524.9M-13.1%2.49
2026-05-2928.6M-23.5%3.47
2026-05-1537.4M-4.3%4.60
2026-04-3039.1M-3.7%6.40

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$1.92B$1.37B$1.26B$1.10B$1.47B
Gross profit
Operating income$-85.5M$-45.7M$-205.3M$-286.7M$-637.0M
Net income$-85.5M$-43.0M$-213.4M$-339.6M$-587.8M
Diluted EPS$-0.44$-0.71$-1.42

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2025FY2024FY2023FY2022FY2021
Cash and equivalents$78.3M$194.5M$122.9M$103.8M$300.0M
Current assets$307.9M$343.1M$428.0M$625.0M$752.5M
Total assets$541.0M$580.7M$570.7M$808.6M$950.8M
Current liabilities$208.8M$213.5M$261.1M$431.5M$371.9M
Long-term debt$0$19.9M
Total liabilities$232.3M$239.6M$284.3M$451.7M$410.8M
Total equity$308.7M$341.1M$286.4M$356.9M$540.0M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$-66.9M$34.8M$-144.7M$-203.9M$-282.3M
Capital expenditure$2.0M$1.6M$584,000$4.5M$723,000
Free cash flow$-69.0M$33.3M$-145.2M$-208.4M$-283.0M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$743.2M55.6%$28.0M$0.05
Q1 FY2026$749.2M62.0%$27.3M$0.05
Q4 FY2025$487.7M44.7%
Q3 FY2025$496.6M50.1%$-24.4M
Q2 FY2025$477.6M34.1%$-10.6M$-0.02
Q1 FY2025$462.3M33.3%$-1.3M$0.00
Q4 FY2024$337.0M7.9%
Q3 FY2024$331.0M8.2%$-9.2M

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNasdaq
SectorFinancials
SIC industryHospital & Medical Service Plans
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2020
SEC CIK1801170

Selected SEC filings

10-Q2026-08-07
View on EDGAR →
10-Q2026-05-08
View on EDGAR →
8-K2026-08-20
View on EDGAR →
8-K2026-08-05
View on EDGAR →
8-K2026-07-17
View on EDGAR →
8-K2026-06-18
View on EDGAR →

Largest Financials peers

All Financials companies →

Monitor CLOV

Get an alert when Clover Health Investments, Corp. /de files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor CLOV free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.